3 not yet recruiting. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow JSKN033: new trials by email Literature Review of JSKN033 trials Research Report on JSKN033
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer JSKN033, Docetaxel, Topotecan - Recurrent or Metastatic Cervical Cancer | Phase 3 | Not yet recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 368 | 2026-09-01 | 2026-09-01 |
| JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer JSKN033, Platinum, Bevacizumab - Cervical Cancer | Phase 2 | Not yet recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 78 | 2026-04-01 | 2026-03-27 |
| JSKN033 in Chinese Subjects with Advanced Malignant Tumors JSKN033 - Advanced Malignant Tumors | Phase 1 / Phase 2 | Not yet recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 430 | 2025-01-15 | 2025-01-13 |
Uterine Cervical Neoplasms (2) · Recurrence (1)
Jiangsu Alphamab Biopharmaceuticals Co., Ltd (3)
China (2)
XiaoHua Wu, MD (1)